Arno Therapeutics, Inc. (Arno Therapeutics) is a bio pharmaceutical company engaged in the development of innovative products for the treatment of cancer. The company focuses on acquiring the rights to pre-clinical and early stage oncology products from various academic and research institutions and develop them for commercial use. The company currently focuses on developing its portfolio of pipeline products, which includes: AR-67, AR-12 and AR-42. In June 2008, the company was acquired by Laurier International, Inc. In May, Arno Therapeutics voluntarily filed a Form 15 with the Securities and Exchange Commission (SEC) for deregistering its common stock under the Securities and Exchange Act of 1934. The company is headquartered in New Jersey, the US.